The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer

被引:0
作者
Wakako Tajiri
Hideki Ijichi
Katsumi Takizawa
Yumiko Koi
Takanobu Masuda
Hiroki Ueo
Chinami Koga
Yoshiaki Nakamura
Kenichi Taguchi
Masahiro Okamoto
Eriko Tokunaga
机构
[1] National Hospital Organization Kyushu Cancer Center,Department of Breast Oncology
[2] National Hospital Organization Kyushu Cancer Center,Department of Pathology
关键词
Breast cancer; ER+; Endocrine therapy; Late distant recurrence; CTS5;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:67 / 74
页数:7
相关论文
共 171 条
[1]  
DeSantis CE(2019)Breast cancer statistics, 2019 CA Cancer J Clin 69 438-451
[2]  
Ma J(2012)Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project Jpn J Clin Oncol 42 139-147
[3]  
Gaudet MM(2015)Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011 Breast Cancer. 22 235-244
[4]  
Newman LA(2015)Breast cancer screening and the changing population pyramid of Japan Breast Cancer. 22 172-176
[5]  
Miller KD(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717
[6]  
Goding Sauer A(2016)Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V J Clin Oncol 34 927-935
[7]  
Matsuda T(2017)20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years N Engl J Med 377 1836-1846
[8]  
Marugame T(2015)Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor Int J Clin Oncol. 20 249-252
[9]  
Kamo K(2013)Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 805-816
[10]  
Katanoda K(2005)Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 1262-1271